These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24645950)

  • 1. Movement toward optimization of CLL therapy.
    Rai KR; Barrientos JC
    N Engl J Med; 2014 Mar; 370(12):1160-2. PubMed ID: 24645950
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoimmunotherapy for chronic lymphocytic leukemia.
    Spehn J; Mühlbauer B
    N Engl J Med; 2014 Jun; 370(24):2348. PubMed ID: 24918384
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoimmunotherapy for chronic lymphocytic leukemia. Author reply.
    Goede V; Fischer K; Hallek M
    N Engl J Med; 2014 Jun; 370(24):2348-9. PubMed ID: 24918383
    [No Abstract]   [Full Text] [Related]  

  • 4. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
    Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
    J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
    Brown JR
    Oncology (Williston Park); 2015 Jun; 29(6):442, 444. PubMed ID: 26091679
    [No Abstract]   [Full Text] [Related]  

  • 12. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
    Goede V; Fischer K; Engelke A; Schlag R; Lepretre S; Montero LF; Montillo M; Fegan C; Asikanius E; Humphrey K; Fingerle-Rowson G; Hallek M
    Leukemia; 2015 Jul; 29(7):1602-4. PubMed ID: 25634683
    [No Abstract]   [Full Text] [Related]  

  • 13. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
    Fakhri B; Andreadis C
    Oncology (Williston Park); 2019 Nov; 33(11):. PubMed ID: 31769861
    [No Abstract]   [Full Text] [Related]  

  • 14. Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.
    Autore F; Fresa A; Innocenti I; Tomasso A; Morelli F; Corbingi A; Sorà F; Laurenti L
    Hematol Oncol; 2019 Dec; 37(5):641-643. PubMed ID: 31604368
    [No Abstract]   [Full Text] [Related]  

  • 15. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia.
    Pejsa V; Lucijanic M; Jonjic Z; Prka Z; Vukorepa G
    Ann Hematol; 2019 Jun; 98(6):1509-1510. PubMed ID: 30421169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.